Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resection Margin Strategy in Breast Conservative Surgery After Neoadjuvant Therapy
NCT03417622Phase 3Recruiting
- Sponsor
- Mansoura University
- Start
- Aug 2019
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Mansoura University. Primary endpoint: Local recurrence rate at 60 months. Started Aug 2019; status: recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03417622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417622.